

IN THE UNITED STATES DESIGNATED/ELECTED OFFICE

International Application No. PCT/EP2004/001370 : International Filing Date 13 February 2004 (13.02.2004) U.S. Serial No. 10/510,578 Deposit Date U.S. Nat'l Phase : 08 October 2004 (08.10.2004) Priority Date(s) Claimed 13 February 2003 (13.02.2003) : Applicant(s) (DO/EO/US) Karlheinz DOSER et al. Title: SALT OF A SULFONIC ACID CONTAINING CLOPIDOGREL AND USE THEREOF FOR THE PRODUCTION OF PHARMACEUTICAL FORMULATIONS INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §§ 1.56, 1.97 and 1.98 Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450 Sir: This information disclosure statement is made in accordance with 37 C.F.R. §§ 1.56, 1.97 and 1.98 as follows: Timing and Fees \boxtimes Under 37 C.F.R. § 1.97(b), no fee or statement is required for filing this information disclosure statement is filed: within three months of the filing date of a national application other than a CPA under § 1.53(d); within three months of the actual filing date of the national phase of a PCT application; OR X before the mailing of a first substantive office action (including after filing of an RCE). Under 37 C.F.R. § 1.97(c), this information disclosure statement is filed after the periods

a final rejection under 37 C.F.R. 1.113; termination of prosecution, e.g. Ex Parte Quayle, M.P.E.P § 609(B)(2); OR a notice of allowance under 37 C.F.R. § 1.311; and

specified in 37 C.F.R. § 1.97(b), but before the mailing date of:

		is accompanied by:						
			the statement as specified in 37 C.F.R. § 1.97(e) set out below; OR					
			a check covering the fee of \$180.00 under 37 C.F.R. § 1.17(p).					
			R. § 1.97(d), this information disclosure statement is filed after the mailing lowing actions which have not been withdrawn:					
		a final	action under 37 C.F.R. § 1.113;					
		termin	ation of prosecution, e.g. Ex Parte Quayle, M.P.E.P § 609(B)(2);					
		OR a r	notice of allowance under 37 C.F.R. § 1.311;					
	AND i	s filed o	on or before payment of the issue fee; AND is accompanied by:					
			tement as specified in 37 C.F.R. § 1.97(e) as set forth below, and the fee of 00 under 37 C.F.R. § 1.17(p).					
Staten	nents Ur	nder 37	C.F.R. 1.97(e)					
			Each item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application having a mailing date not more than three months prior to the filing date of this information disclosure statement; or					
			No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and to the knowledge of the undersigned attorney after making reasonable inquiry, no item of information contained in this information disclosure statement was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing date of the information disclosure statement.					
Cited]	Materia	<u>ls</u>						
		ancest	s of materials listed but not attached were cited in benefit (35 U.S.C. § 120) or application Serial No, on Form 892 by the Examiner and/or Form by the applicant; see 37 C.F.R. § 1.98(d).					
		_	s of materials listed but not attached were cited in an international search dated					
	\boxtimes	Not re	quired by 37 CFR § 1.98.					
		Copies	s of the materials listed are attached (except for the foregoing).					
			2					

Non-English	Language References						
	An English-language search report or equivalent paper from a foreign patent office is provided indicating the relevance of the cited reference(s).						
	A foreign-language search report from a foreign patent office is provided, and pertinent parts are translated substantively below:						
	 X = document of particular relevance when it is taken alone Y = document of particular relevance when it is combined with another such document A = document defining the general state of the art O = non-written disclosure P = intercalated document T = document cited to understand the theory or principle underlying the invention E = patent document which has the benefit of a date earlier than the filing date and which was published only on or after this filing date D = cited in the application L = cited for another reason & = publication of member of same patent family 						
	Translation of other relevant information on foreign search report						
Other Inform	<u>nation</u>						
	Fees Due (If Any): eck for \$ covering the fee identified above is attached.						
Plea	se charge to Deposit Account No. 13-3402 \$ for the fee identified above.						

 \boxtimes The Commissioner is hereby authorized to charge or credit any overpayment to Deposit Account #13-3402, two copies of this paper are attached for this purpose.

Respectfully submitted,

Anthony J. Zelano, Reg. No. 27,969 Attorney/Agent for Applicants

MILLEN, WHITE, ZELANO & BRANIGAN, P.C. Arlington Courthouse Plaza l 2200 Clarendon Blvd. Suite 1400 Arlington, Virginia 22201 Telephone: (703) 243-6333

Facsimile: (703) 243-6410

Attorney Docket No.: LEDER-0011

Date: May 10, 2005

AJZ:ssr

Please t	ype a į	plus sign	(+)	inside	this	box	\rightarrow	+
----------	---------	-----------	-----	--------	------	-----	---------------	---

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO Complete if Known Application Number 10/510,578 INFORMATION DISCLOSURE 08 October 2004(08.10.2004) Filing Date STATEMENT BY APPLICANT First Named Inventor Karlheinz DOSER et al. Group Art Unit unknown (use as many sheets as necessary) Examiner Name unknown Attorney Docket Number of LEDER-0011 Sheet

U.S. PATENT DOCUMENTS							
Examiner	-	U.S. Patent Document	Kind Code ²		Date of Publication of Cited Document		
Initials *	Cite No.1	Number	(if known)	The state of the state of the product	MM-DD-YYYY		
	001	4,529,596		AUBERT, et al.	07-16-1985		
•							
· · · · · · · · · · · · · · · · · · ·							
					Ť		
	-						

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No.1	Office ³	Foreign Patent Docum	ent Kind Code ⁵ (if known)		Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
	002	DE	101 53 078.1		DEGUSSA AG	10-30-2001		
	003	DE	101 09 763.8		GRUENENTHAL GMBH	02-28-2001		
	004	DE	697 13 287.0		TER MEER STEINMEISTER	08-21-1997		
<u> </u>								
		<u> </u>						
	1		1	1				l

Examiner Signature	Date Considered	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, Include copy of this form with next communication to applicant,

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached. Number refers to English language corresponding family member.